Skip to main content
Equibles
FULC logo

FULC · Fulcrum Therapeutics, Inc.

Track FULC — free

Use FULC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about FULC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.85 -0.01 (-0.26%) At close · Aug 27
Market Cap
$293.74M
Shares
76.30M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.85 Open$3.86 Day$3.83–3.89 52W close$3.14–14.60 Avg vol 30d1.6M Short int6.7M · 8.7% float · 5.0d Short vol48% Last earningsApr 27, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −48%
      below
      Price vs 50-day avg +3%
      above
      RSI (14) 53
      neutral
      MACD trend Positive
      52-week position 6%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +3%
      trailing
      6-month return −53%
      trailing
      YTD return −66%
      this year
      Relative strength −68%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $4 › 200d $7 — 200d above 50d
      Institutional flow Distributing
      -9% holders QoQ · +29 funds added
      Insider flow Accumulating
      Net +$1.4M over 90 days · 50% sells
      Short interest Rising
      8.72% of float · ▲ +0.4% MoM · 5.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      154 holders — mid 3-yr range
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth −100%
      Y/Y
      EPS growth −638%
      Y/Y
      Free cash flow $-60.4M
      Balance sheet $197.5M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 98%
      annualized · 1-yr
      Max drawdown −78%
      past year
      ATR 3.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Jun 30, 2022
      Savings from realignment $40M – $50M
      extends our runway into mid-2024
      Savings $40M – $50M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −48% Bearish
      Price vs 50-day avg
      +3% Bullish
      RSI (14)
      53 Neutral
      MACD trend
      Positive Bullish
      52-week position
      6% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $4 › 200d $7 — 200d above 50d
      Institutional flow Distributing
      -9% holders QoQ · +29 funds added
      Insider flow Accumulating
      Net +$1.4M over 90 days · 50% sells
      Short interest Rising
      8.72% of float · ▲ +0.4% MoM · 5.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      154 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $3 Now $4 · 6% Range high $15
      vs 200-day avg -48% vs 50-day avg +3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      cash, cash equivalents, and marketable securities $333.3M first quarter 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      FULC
      Fulcrum Therapeutics, Inc.
      this stock
      		$293.74M -66.0% -100.0% — 8.7%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.72B +20.8% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $83.89B +4.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      		 $65.12B +25.9% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.92B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      154
      % held
      104.9%
      Net QoQ
      +7.6M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      159
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      6.7M
      Days to cover
      5.0d
      Change
      +24.7K sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      14.1K
      Value
      $49.3K
      As of
      Jul 17, 2026
      View
      Off-Exchange
      Off-exchange %
      33.4%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$1.4M
      Buyers / Sellers
      1 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-74.9M
      EPS diluted
      $-1.18
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 17, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $65.0K
      Shares
      18.0K
      Filed
      Jun 26, 2026
      View
      Exempt Offerings
      Offering
      $68.5M
      Filed
      Jun 11, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Apr 27, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      FULC +0.0% +3.5% -52.9% +7.5% -66.0%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY -1.1% -0.5% -67.6% +4.3% -79.0%
      Key facts CIK 1680581 CUSIP 359616109 13F (30d) 140 filings 137 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)